2 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Lynch Syndrome: new trials by email Literature Review of Lynch Syndrome trials Research Report on Lynch Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventive Dendritic Cell Vaccination for Lynch Syndrome DC vaccination - Lynch Syndrome | Phase 1 / Phase 2 | Not yet recruiting | Radboud University Medical Center | 16 | 2026-10-01 | 2026-08-19 |
| First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers Autologous Tolerogenic Dendritic cells - Lynch Syndrome | Phase 1 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | 20 | 2025-09-04 | 2026-04-13 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy - Colorectal Carcinoma, Lynch Syndrome | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 45 | 2022-11-10 | 2026-03-03 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome Laboratory Biomarker Analysis, Naproxen, Placebo Administration - Lynch Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 81 | 2014-01-27 | 2021-01-25 |
Colorectal Neoplasms, Hereditary Nonpolyposis (6) · Turcot syndrome (2) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Familial ependymoma (1) · Glioma (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Medulloblastoma (1) · Neuroblastoma (1) · Xeroderma Pigmentosum (1)
Colonic Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · DNA Repair-Deficiency Disorders (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Genetic Diseases, Inborn (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Metabolic Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Neoplastic Syndromes, Hereditary (6) · Nutritional and Metabolic Diseases (6)
Specimen Handling (3) · Biopsy (1) · CTLA-4 Antigen (1) · Diffusion Tensor Imaging (1) · Endoscopic Mucosal Resection (1) · Endoscopy (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Naproxen (1) · Nivolumab (1) · pembrolizumab (1)
National Cancer Institute (NCI) (4) · Fundacion Clinic per a la Recerca Biomédica (1) · Radboud University Medical Center (1)
United States (4) · Canada (2) · Netherlands (1) · Puerto Rico (1) · Spain (1)
Eduardo Vilar-Sanchez (2) · Daniel A Morgenstern (1) · Eugene I Hwang (1)
P30CA016672 (2), 2025 (1), N01CN00034 (1), P30CA015704 (1), UG1CA242609 (1), UM1CA081457 (1), UM1CA154967 (1)